Flexion Co-Founder, Chief Scientific Officer Neil Bodick to Retire

Neil Bodick, chief scientific officer of Flexion Therapeutics (NASDAQ: [[ticker:FLXN]]), will retire on Jan. 3. After co-founding the company in 2007, Bodick served as its chief medical officer. He became chief scientific officer in 2017 following FDA approval of the company’s extended-release formulation of triamcinolone acetonide (Zilretta), a treatment for knee pain. After retiring, Flexion says Bodick will continue in a consulting role to help in the transition of his responsibilities. Burlington, MA-based Flexion develops therapies for musculoskeletal conditions.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan